{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:10:37Z","timestamp":1778361037557,"version":"3.51.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guiding Plan of Xinjiang Production, Construction Corps","award":["No. 2024ZD062"],"award-info":[{"award-number":["No. 2024ZD062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01392-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:25:54Z","timestamp":1778315154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence"],"prefix":"10.1007","volume":"27","author":[{"given":"Yunfei","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"6","key":"1392_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s43018-025-00996-1","volume":"6","author":"A Thomas","year":"2025","unstructured":"Thomas A, Mohindroo C, Giaccone G. Advancing therapeutics in small-cell lung cancer. Nat Cancer. 2025;6(6):938. https:\/\/doi.org\/10.1038\/s43018-025-00996-1.","journal-title":"Nat Cancer"},{"issue":"12","key":"1392_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725\u201337. https:\/\/doi.org\/10.1038\/nrc.2017.87.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"1392_CR3","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC. Small cell lung cancer: a review. JAMA. 2025;333(21):1906\u201317. https:\/\/doi.org\/10.1001\/jama.2025.0560.","journal-title":"JAMA"},{"issue":"3","key":"1392_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1392_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006849.pub3","volume":"2015","author":"IU Amarasena","year":"2015","unstructured":"Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2015;2015(8):Cd006849. https:\/\/doi.org\/10.1002\/14651858.CD006849.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1392_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s43018-025-00992-5","volume":"6","author":"K Qin","year":"2025","unstructured":"Qin K, Gay CM, Byers LA, Zhang J. The current and emerging immunotherapy paradigm in small-cell lung cancer. Nat Cancer. 2025;6(6):954\u201366. https:\/\/doi.org\/10.1038\/s43018-025-00992-5.","journal-title":"Nat Cancer"},{"key":"1392_CR7","doi-asserted-by":"publisher","unstructured":"[Clinical practice guideline for brain metastases of lung cancer in China. (2021 version)]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2021;43(3):269\u201381. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210104-00009","DOI":"10.3760\/cma.j.cn112152-20210104-00009"},{"key":"1392_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100566","volume":"44","author":"S Kalantri","year":"2025","unstructured":"Kalantri S, Sainatham C, Gaddipati GN, Tallapalli JR, Singh R, Kloecker GH. Patient-centered perspectives: examining quality-of-life integration in recent phase III lung cancer trials (2019\u20132023). J Cancer Policy. 2025;44:100566. https:\/\/doi.org\/10.1016\/j.jcpo.2025.100566.","journal-title":"J Cancer Policy"},{"key":"1392_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104618","volume":"207","author":"P Damiano","year":"2025","unstructured":"Damiano P, Stefani A, Avancini A, Belluomini L, Bria E, Pilotto S. Real-world evidence in extensive disease small cell lung cancer: the missing piece of the puzzle. Crit Rev Oncol Hematol. 2025;207:104618. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104618.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1392_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11864-001-0017-5","volume":"2","author":"N Murray","year":"2001","unstructured":"Murray N, Sheehan F. Limited stage small cell lung cancer. Curr Treat Options Oncol. 2001;2(1):63\u201370. https:\/\/doi.org\/10.1007\/s11864-001-0017-5.","journal-title":"Curr Treat Options Oncol"},{"key":"1392_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103014","volume":"140","author":"Y Yu","year":"2025","unstructured":"Yu Y, Luo Y, Zeng F, Liu A. Opportunities and challenges for non-small cell lung cancer brain metastases in the immunotherapy era. Cancer Treat Rev. 2025;140:103014. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103014.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"1392_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441\u201364. https:\/\/doi.org\/10.6004\/jnccn.2021.0058.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"1392_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166557","volume":"1868","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022;1868(12):166557. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166557.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"7","key":"1392_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/nejm199908123410703","volume":"341","author":"A Aup\u00e9rin","year":"1999","unstructured":"Aup\u00e9rin A, Arriagada R, Pignon JP, Le P\u00e9choux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476\u201384. https:\/\/doi.org\/10.1056\/nejm199908123410703.","journal-title":"N Engl J Med"},{"issue":"7","key":"1392_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664\u201372. https:\/\/doi.org\/10.1056\/NEJMoa071780.","journal-title":"N Engl J Med"},{"issue":"5","key":"1392_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663\u201371. https:\/\/doi.org\/10.1016\/s1470-2045(17)30230-9.","journal-title":"Lancet Oncol"},{"key":"1392_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108334","volume":"200","author":"G Stewart","year":"2025","unstructured":"Stewart G, Senan S, Spigel DR, Cho BC, Laktionov K, Zenke Y, et al. 225 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial. Lung Cancer. 2025;200:108334. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108334.","journal-title":"Lung Cancer"},{"issue":"3","key":"1392_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2024.11.011","volume":"20","author":"A Levy","year":"2025","unstructured":"Levy A, Rusthoven CG, Brown PD, Le P\u00e9choux C, Faivre-Finn C. Prophylactic cranial irradiation for patients with SCLC-a new perspective in the immunotherapy era. Journal of Thoracic Oncology. 2025;20(3):395\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2024.11.011.","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"1392_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1023\/a:1005761825766","volume":"35","author":"M van de Pol","year":"1997","unstructured":"van de Pol M, ten Velde GP, Wilmink JT, Volovics A, Twijnstra A. Efficacy and safety of prophylactic cranial irradiation in patients with small cell lung cancer. Journal of neuro-oncology. 1997;35(2):153\u201360. https:\/\/doi.org\/10.1023\/a:1005761825766.","journal-title":"Journal of neuro-oncology"},{"issue":"3","key":"1392_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","volume":"10","author":"CB Simone 2nd","year":"2020","unstructured":"Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline. Practical radiation oncology. 2020;10(3):158\u201373. https:\/\/doi.org\/10.1016\/j.prro.2020.02.009.","journal-title":"Practical radiation oncology"},{"issue":"7","key":"1392_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Annals of Oncology. 2021;32(7):839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Annals of Oncology"},{"issue":"4","key":"1392_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2007.02.016","volume":"68","author":"A Ghia","year":"2007","unstructured":"Ghia A, Tom\u00e9 WA, Thomas S, Cannon G, Khuntia D, Kuo JS, et al. Distribution of brain metastases in relation to the hippocampus: Implications for neurocognitive functional preservation. International journal of radiation oncology, biology, physics. 2007;68(4):971\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.02.016.","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"3","key":"1392_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.radonc.2010.02.030","volume":"95","author":"V Gondi","year":"2010","unstructured":"Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and Oncology. 2010;95(3):327\u201331. https:\/\/doi.org\/10.1016\/j.radonc.2010.02.030.","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"1392_CR24","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ijrobp.2010.01.039","volume":"78","author":"V Gondi","year":"2010","unstructured":"Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: A \u201chow-to\u201d technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. International journal of radiation oncology, biology, physics. 2010;78(4):1244\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.039.","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"10","key":"1392_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/jco.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG Oncology CC001. Journal of Clinical Oncology. 2020;38(10):1019\u201329. https:\/\/doi.org\/10.1200\/jco.19.02767.","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"1392_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cllc.2025.06.003","volume":"26","author":"SD Robinson","year":"2025","unstructured":"Robinson SD, Wong CD, Mazarakis NK, Lorimer C, Critchley G, Chandy E. A review of focal therapies for small cell lung cancer brain metastases. Clin Lung Cancer. 2025;26(6):441\u201357. https:\/\/doi.org\/10.1016\/j.cllc.2025.06.003.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"1392_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","volume":"6","author":"CG Rusthoven","year":"2020","unstructured":"Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, et al. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol. 2020;6(7):1028\u201337. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1271.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1392_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/s1470-2045(22)00271-6","volume":"23","author":"K Gaebe","year":"2022","unstructured":"Gaebe K, Li AY, Park A, Parmar A, Lok BH, Sahgal A, et al. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. Lancet Oncol. 2022;23(7):931\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(22)00271-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1392_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.08.031","volume":"117","author":"D Bernhardt","year":"2023","unstructured":"Bernhardt D, El Shafie R, Thomas M, Bozorgmehr F, Schiele A, Schmitt D, et al. Stereotactic radiotherapy vs. whole brain radiation therapy for patients with 1\u201310 brain metastases from small cell lung cancer: Results of the randomized ENCEPHALON (ARO 2018-9) trial. Int J Radiat Oncol Biol Phys. 2023;117(4):e5. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"1392_CR30","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/jco-25-00056","volume":"43","author":"AA Aizer","year":"2025","unstructured":"Aizer AA, Tanguturi SK, Shi DD, Catalano PJ, Shin KY, Ricca I, et al. Stereotactic radiosurgery in patients with small cell lung cancer and 1\u201310 brain metastases: A multi-institutional, Phase II, prospective clinical trial. J Clin Oncol. 2025;43(27):2986\u201397. https:\/\/doi.org\/10.1200\/jco-25-00056.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1392_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330. https:\/\/doi.org\/10.1200\/jco.20.01055.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1392_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100330","volume":"3","author":"Y Chen","year":"2022","unstructured":"Chen Y, Paz-Ares L, Reinmuth N, Garassino MC, Statsenko G, Hochmair MJ, et al. Impact of brain metastases on treatment patterns and outcomes with first-line Durvalumab plus platinum-etoposide in extensive-stage SCLC (CASPIAN): A brief report. JTO Clin Res Rep. 2022;3(6):100330. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100330.","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"1392_CR33","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022;328(12):1223\u201332. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"issue":"10","key":"1392_CR34","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024;30(10):2967\u201376. https:\/\/doi.org\/10.1038\/s41591-024-03132-1.","journal-title":"Nat Med"},{"issue":"6","key":"1392_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1392_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol. 2025;11(1):16\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5019.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1392_CR37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus Platinum and Etoposide versus placebo plus Platinum and Etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19(7):1073\u201385. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008.","journal-title":"J Thorac Oncol"},{"issue":"10, Supplement","key":"1392_CR38","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jtho.2024.09.060","volume":"19","author":"NJ Choudhury","year":"2024","unstructured":"Choudhury NJ, Beltran H, Johnson ML, Schenk EL, Sanborn RE, Thompson JR, et al. OA10.06 impact of brain metastases on safety and efficacy of MK-6070, a DLL3-targeting T cell engager, in small cell lung cancer. J Thorac Oncol. 2024;19(10, Supplement):S32\u20133. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.060.","journal-title":"J Thorac Oncol"},{"issue":"suppl_2","key":"1392_CR39","doi-asserted-by":"publisher","first-page":"S1479","DOI":"10.1016\/j.annonc.2025.08.3371","volume":"36","author":"PF Simoes da Rocha","year":"2025","unstructured":"Simoes da Rocha PF, Kim YJ, Han J, Johnson ML, Nishio M, Chen Y, et al. 2760MO intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): primary analysis of IDeate-Lung01. Ann Oncol. 2025;36(suppl_2):S1479\u2013501. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3371.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1392_CR40","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1200\/JCO.2025.43.16_suppl.3041","volume":"43","author":"MR Patel","year":"2025","unstructured":"Patel MR, Wu Y-LLC, Wang Z, Rocha P, Wang Q, Du Y, et al. ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. J Clin Oncol. 2025;43(16suppl):3041. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3041.","journal-title":"J Clin Oncol"},{"issue":"29","key":"1392_CR41","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","volume":"42","author":"A Dowlati","year":"2024","unstructured":"Dowlati A, Hummel H-D, Champiat S, Olmedo ME, Boyer M, He K, et al. Sustained clinical benefit and intracranial activity of Tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update. J Clin Oncol. 2024;42(29):3392\u20139. https:\/\/doi.org\/10.1200\/JCO.24.00553.","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"1392_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8008","volume":"43","author":"CM Rudin","year":"2025","unstructured":"Rudin CM, Mountzios GS, Sun L, Cho BC, Demirci U, Baka S, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304. J Clin Oncol. 2025;43(17_suppl):LBA8008-LBA. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA8008.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1392_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","volume":"42","author":"W Xiao","year":"2017","unstructured":"Xiao W, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer. Clin Nucl Med. 2017;42(9):704\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000001763.","journal-title":"Clin Nucl Med"},{"key":"1392_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105068","volume":"102","author":"IJ Pruis","year":"2024","unstructured":"Pruis IJ, van Doormaal PJ, Balvers RK, van den Bent MJ, Harteveld AA, de Jong LC, et al. Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: a single centre, open label, non-randomised prospective imaging study. EBioMedicine. 2024;102:105068. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105068.","journal-title":"EBioMedicine"},{"issue":"8_Supplement_1","key":"1392_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1538-7445.AM2025-346","volume":"85","author":"A Croset","year":"2025","unstructured":"Croset A, Saidi A, Malvezzi F, Stallons T, Mettier M, Wong A, et al. Abstract 346: MP0712, the first anti-DLL3 212Pb radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC). Cancer Res. 2025;85(8_Supplement_1):346. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-346.","journal-title":"Cancer Res"},{"key":"1392_CR46","doi-asserted-by":"publisher","unstructured":"Swarm RA, Youngwerth JM, Agne JL, Anitescu M, Are M, Buga S, et al. Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Cancer Network: JNCCN. 2025;23(7). https:\/\/doi.org\/10.6004\/jnccn.2025.0032.","DOI":"10.6004\/jnccn.2025.0032"},{"issue":"6","key":"1392_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/jco.21.01639","volume":"40","author":"JA Bogart","year":"2022","unstructured":"Bogart JA, Waqar SN, Mix MD. Radiation and systemic therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2022;40(6):661\u201370. https:\/\/doi.org\/10.1200\/jco.21.01639.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1392_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/s1470-2045(22)00288-1","volume":"23","author":"KER Smith","year":"2022","unstructured":"Smith KER, Mansfield AS. Validating chemoimmunotherapy in small-cell lung cancer. Lancet Oncol. 2022;23(6):692\u20133. https:\/\/doi.org\/10.1016\/s1470-2045(22)00288-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1392_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1200\/jco.2017.75.9589","volume":"36","author":"PD Brown","year":"2018","unstructured":"Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-brain radiotherapy for brain metastases: evolution or revolution? J Clin Oncol. 2018;36(5):483\u201391. https:\/\/doi.org\/10.1200\/jco.2017.75.9589.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1392_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1392_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025;393(4):349\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2502099.","journal-title":"N Engl J Med"},{"issue":"5","key":"1392_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","volume":"26","author":"FJ Bolte","year":"2025","unstructured":"Bolte FJ, Dougherty SC, Danos AO, Lynch AC, Shvorak Y, Statler S, et al. Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases. Clin Lung Cancer. 2025;26(5):347\u2013e531. https:\/\/doi.org\/10.1016\/j.cllc.2025.03.006.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1392_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1392_CR54","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","volume":"46","author":"MJ Taphoorn","year":"2010","unstructured":"Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J cancer (Oxford England: 1990). 2010;46(6):1033\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2010.01.012.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"4","key":"1392_CR55","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jpainsymman.2019.11.015","volume":"59","author":"ML Saphire","year":"2020","unstructured":"Saphire ML, Prsic EH, Canavan ME, Wang SJ, Presley CJ, Davidoff AJ. Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer. J Pain Symptom Manag. 2020;59(4):767\u201377. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.11.015.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"1392_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/jco.21.01710","volume":"40","author":"JS Temel","year":"2022","unstructured":"Temel JS, Petrillo LA, Greer JA. Patient-Centered Palliative Care for Patients With Advanced Lung Cancer. J Clin oncology: official J Am Soc Clin Oncol. 2022;40(6):626\u201334. https:\/\/doi.org\/10.1200\/jco.21.01710.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"2","key":"1392_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11060-022-04067-8","volume":"159","author":"A Bunevicius","year":"2022","unstructured":"Bunevicius A, Donovan L, Sheehan J. Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review. J Neurooncol. 2022;159(2):319\u201331. https:\/\/doi.org\/10.1007\/s11060-022-04067-8.","journal-title":"J Neurooncol"},{"key":"1392_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2021.05.019","volume":"161","author":"A Kavi","year":"2021","unstructured":"Kavi A, Gurewitz J, Benjamin CG, Silverman JS, Bernstein K, Mureb M, et al. Hippocampal sparing in patients receiving radiosurgery for \u226525 brain metastases. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2021;161:65\u201371. https:\/\/doi.org\/10.1016\/j.radonc.2021.05.019.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"key":"1392_CR59","doi-asserted-by":"publisher","first-page":"1342669","DOI":"10.3389\/fonc.2024.1342669","volume":"14","author":"R Liu","year":"2024","unstructured":"Liu R, Gong G, Meng K, Du S, Yin Y. Hippocampal sparing in whole-brain radiotherapy for brain metastases: controversy, technology and the future. Front Oncol. 2024;14:1342669. https:\/\/doi.org\/10.3389\/fonc.2024.1342669.","journal-title":"Front Oncol"},{"issue":"4","key":"1392_CR60","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.beha.2023.101523","volume":"36","author":"RP Gale","year":"2023","unstructured":"Gale RP, Zhang MJ, Lazarus HM. The role of randomized controlled trials, registries, observational databases in evaluating new interventions. Best Pract Res Clin Haematol. 2023;36(4):101523. https:\/\/doi.org\/10.1016\/j.beha.2023.101523.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"1392_CR61","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/s2589-7500(24)00047-5","volume":"6","author":"R Han","year":"2024","unstructured":"Han R, Acosta JN, Shakeri Z, Ioannidis JPA, Topol EJ, Rajpurkar P. Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review. Lancet Digit health. 2024;6(5):e367\u201373. https:\/\/doi.org\/10.1016\/s2589-7500(24)00047-5.","journal-title":"Lancet Digit health"},{"issue":"9","key":"1392_CR62","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s00125-020-05217-1","volume":"63","author":"M Gokhale","year":"2020","unstructured":"Gokhale M, St\u00fcrmer T, Buse JB. Real-world evidence: the devil is in the detail. Diabetologia. 2020;63(9):1694\u2013705. https:\/\/doi.org\/10.1007\/s00125-020-05217-1.","journal-title":"Diabetologia"},{"issue":"23","key":"1392_CR63","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"key":"1392_CR64","doi-asserted-by":"publisher","first-page":"S1673","DOI":"10.1016\/j.annonc.2023.10.599","volume":"34","author":"Y Namgung","year":"2023","unstructured":"Namgung Y, Lee K, Choi J, Lee SY, Kang EJ. 520P Role of atezolizumab in controlling CNS progression in ES-SCLC. Ann Oncol. 2023;34:S1673\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.599.","journal-title":"Ann Oncol"},{"issue":"7","key":"1392_CR65","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s12094-024-03387-7","volume":"26","author":"H Chen","year":"2024","unstructured":"Chen H, Ma X, Liu J, Yang Y, He Y, Fang Y, et al. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum\/etoposide: a focus on patients with brain metastasis. Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2024;26(7):1664\u201373. https:\/\/doi.org\/10.1007\/s12094-024-03387-7.","journal-title":"Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"1","key":"1392_CR66","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12885-025-13880-z","volume":"25","author":"K Zhao","year":"2025","unstructured":"Zhao K, Lu S, Niu J, Zhu H, Tian Y, Yu J. Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer. BMC Cancer. 2025;25(1):467. https:\/\/doi.org\/10.1186\/s12885-025-13880-z.","journal-title":"BMC Cancer"},{"issue":"2","key":"1392_CR67","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.cllc.2023.11.009","volume":"25","author":"M Porte","year":"2024","unstructured":"Porte M, Vaudron A, Crequit P, Vaugier L, Chatellier T, Fronteau C, et al. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients. Clin Lung Cancer. 2024;25(2):e101. https:\/\/doi.org\/10.1016\/j.cllc.2023.11.009.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"1392_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100544","volume":"4","author":"Y Wang","year":"2023","unstructured":"Wang Y, Mathai J, Alamgeer M, Parakh S, Paul E, Mitchell P, et al. Real-world analysis of clinical characteristics and survival outcomes in patients with extensive-stage SCLC treated with first-line chemoimmunotherapy. JTO Clin Res Rep. 2023;4(8):100544. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100544.","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"1392_CR69","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2217\/cer-2018-0066","volume":"7","author":"G Hampson","year":"2018","unstructured":"Hampson G, Towse A, Dreitlein WB, Henshall C, Pearson SD. Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018;7(12):1133\u201343. https:\/\/doi.org\/10.2217\/cer-2018-0066.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1392_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/19466315.2021.1883473","volume":"15","author":"M Levenson","year":"2023","unstructured":"Levenson M, He W, Chen J, Fang Y, Faries D, Goldstein BA, et al. Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment. Stat Biopharm Res. 2023;15(1):3\u201313. https:\/\/doi.org\/10.1080\/19466315.2021.1883473.","journal-title":"Stat Biopharm Res"},{"issue":"1","key":"1392_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1146\/annurev-biodatasci-102423-113220","volume":"7","author":"F Liu","year":"2024","unstructured":"Liu F. Data science methods for real-world evidence generation in real-world data. Annu Rev Biomed Data Sci. 2024;7(1):201\u201324. https:\/\/doi.org\/10.1146\/annurev-biodatasci-102423-113220.","journal-title":"Annu Rev Biomed Data Sci"},{"issue":"3","key":"1392_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jval.2022.09.003","volume":"26","author":"K Khambholja","year":"2023","unstructured":"Khambholja K, Gehani M. Use of structured template and reporting tool for real-world evidence for critical appraisal of the quality of reporting of real-world evidence studies: A systematic review. Value Health. 2023;26(3):427\u201334. https:\/\/doi.org\/10.1016\/j.jval.2022.09.003.","journal-title":"Value Health"},{"issue":"1","key":"1392_CR73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","volume":"59","author":"T St\u00fcrmer","year":"2020","unstructured":"St\u00fcrmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology (Oxford, England). 2020;59(1):14\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/kez320.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"1392_CR74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt.2449","volume":"111","author":"D McNair","year":"2022","unstructured":"McNair D, Lumpkin M, Kern S, Hartman D. Use of RWE to inform regulatory, public health policy, and intervention priorities for the Developing World. Clin Pharmacol Ther. 2022;111(1):44\u201351. https:\/\/doi.org\/10.1002\/cpt.2449.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1392_CR75","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1392_CR76","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s12325-025-03201-y","volume":"42","author":"S Khozin","year":"2025","unstructured":"Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, et al. Real-world evidence acceptability and use in breast cancer treatment decision-making in the United States: Call-to-action from a multidisciplinary think tank. Adv Ther. 2025;42(7):2973\u201387. https:\/\/doi.org\/10.1007\/s12325-025-03201-y.","journal-title":"Adv Ther"},{"key":"1392_CR77","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919899852","volume":"12","author":"R Caccialanza","year":"2020","unstructured":"Caccialanza R, Goldwasser F, Marschal O, Ottery F, Schiefke I, Tilleul P, et al. Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. Ther Adv Med Oncol. 2020;12:1758835919899852. https:\/\/doi.org\/10.1177\/1758835919899852.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1392_CR78","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpt.2480","volume":"111","author":"S Dagenais","year":"2022","unstructured":"Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin Pharmacol Ther. 2022;111(1):77\u201389. https:\/\/doi.org\/10.1002\/cpt.2480.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1392_CR79","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1089\/jpm.2021.0533","volume":"25","author":"L Otto-Vollaard","year":"2022","unstructured":"Otto-Vollaard L, Quint S, de Pree IMN, Steinvoort IN, Tims OJL, Nuyttens JJ. Brain metastases: patient-reported outcome and quality of life after whole-brain radiotherapy. J Palliat Med. 2022;25(10):1533\u20139. https:\/\/doi.org\/10.1089\/jpm.2021.0533.","journal-title":"J Palliat Med"},{"issue":"3","key":"1392_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346-360.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014.","journal-title":"Cancer Cell"},{"issue":"1","key":"1392_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05544-x","volume":"150","author":"L Zhu","year":"2024","unstructured":"Zhu L, Qin J. Predictive biomarkers for immunotherapy response in extensive-stage SCLC. J Cancer Res Clin Oncol. 2024;150(1):22. https:\/\/doi.org\/10.1007\/s00432-023-05544-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1392_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35770","volume":"131","author":"MD Shields","year":"2025","unstructured":"Shields MD, Chiang AC, Byers LA. Top advances of the year: small cell lung cancer. Cancer. 2025;131(6):e35770. https:\/\/doi.org\/10.1002\/cncr.35770.","journal-title":"Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01392-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:02:18Z","timestamp":1778360538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01392-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}